参考文献/References:
［1］ Saijo N. Advances in the treatment of non small cell lung cancer［J］. Cancer Treat Rev, 2008, 34: 521 526.
［2］ Wei W, Shen XH, Sun HH, et al. The short term therapeutic effects of radioactive 125I seeds implantation for treatment of non small cell lung cancer［J］. Zhonghua Nei Ke Za Zhi, 2012, 51: 978 981.
［3］ 柴树德， 郑广钧． 胸部肿瘤放射性粒子治疗学［M］． 北京： 人民卫生出版社， 2012： 289 290．
［4］ Wu JY, Wu SG, Yang CH, et al. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations［J］. Lung Cancer, 2011, 72: 205 212.
［5］ Groen H, Arrieta OG, Riska H, et al. The global TRUST study of erlotinib in advanced non small cell lung cancer （NSCLC）［J］. J Clin Oncol, 2008, 26(suppl): abstr 19000.
［6］ Mok T, Wu YL, Au JS, et al. Efficacy and safety of erlotinib in 1242 East/South East Asian patients with advanced non small cell lung cancer［J］. J Thorac Oncol, 2010, 5: 1609 1615.
［7］ Zhou C, Wu Y, Chen G, et al. Updated median PFS and analysis of quality of life（QOL） in OPTIMAL, a phase Ⅲ, randomized, open lable, first line study of erlotinib vs carboplatin/gemcitabine in patients with advanced non small cell lung cancer（NSCLC） with EGFR activating mutations［C］.2011WCLC, O10.02.
［8］ Zhang L, Shenglin M, Song X, et al. Efficacy, tolerability, and biomarker analyses from a phase Ⅲ, randomized， placebo controlled， parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non small cell lung cancer (NSCLC; INFORM; C TONG 0804)［J］, J Clin Oncol, 2011, 29(Suppl): abstr LBA7511.
［9］ Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma［J］. N Engl J Med, 2009, 361: 947 957.
［10］ Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non small cell lung cancer with mutated EGFR［J］. N Engl J Med, 2010, 362: 2380 2388.
［11］ Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial［J］. Lancet Oncol, 2010, 11: 121 128.
［12］ Colquhoun AJ, Mchugh LA, Tulchinsky E, et al. Combination treatment with ionising radiation and gefitinib (‘Iressa’, ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo［J］. J Radiat Res, 2007, 48: 351 360.
［13］ Wang J, Xia TY, Wang YJ, et al. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic Non Small Cell lung cancer［J］. Int J Radiat Oncol Biol Phys, 2011, 81: e59 e65.
［14］ Timmerman R, Mcgarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase Ⅱ study of stereotactic body radiation therapy for medically inoperable early stage lung cancer［J］. J Clin Oncol, 2006, 24: 4833 4839.
［15］ 程永德， 程英升， 颜志平． 常见恶性肿瘤介入治疗指南［M］． 北京： 科学出版社， 2013： 6 8．
相似文献/References:
[1]李任飞,王月东,闫 龑,等.125I粒子植入治疗非小细胞肺癌近期疗效评估[J].介入放射学杂志,2014,(01):65.
LI Ren? fei,WANG Yue? dong,YAN Yan,et al. Implantation of 125I seeds for the treatment of non?蛳 small cell lung cancer： evaluation of short?蛳 term effect[J].journal interventional radiology,2014,(03):65.
[2]宋晶晶,纪建松,赵中伟,等. 支气管动脉化疗栓塞联合125I粒子植入治疗老年性非小细胞肺癌疗效分析[J].介入放射学杂志,2014,(02):159.
SONG Jing? jing,JI Jian? song,ZHAO Zhong? wei,et al. Bronchial artery chemoembolization combined with 125I seeds implantation for the treatment of non?蛳 small cell lung cancer in senile patients： comparison with GP chemotherapy scheme[J].journal interventional radiology,2014,(03):159.
[3]赵真真,王忠敏,茅爱武. 非小细胞肺癌的介入治疗现状[J].介入放射学杂志,2014,(03):272.
ZHAO Zhen? zhen,WANG Zhong? min,MAO Ai? wu.. Current situation of interventional treatment for non?蛳 small cell lung cancer[J].journal interventional radiology,2014,(03):272.
[4]陆 健,刘 琳,陈志瑾,等.进展期非小细胞肺癌125I粒子植入前后CEA、 CYFRA21- 1变化与临床疗效评估[J].介入放射学杂志,2016,(03):234.
LU Jian,LIU Lin,CHEN Zhi- jin,et al.The changes of CEA and CYFRA21- 1 levels after 125I seed implantation in advanced non- small cell lung cancer and their correlation with clinical effectiveness[J].journal interventional radiology,2016,(03):234.
[5]刘 亚,吕维富,成德雷,等.静脉化疗联合125I放射性粒子植入治疗中晚期非小细胞肺癌的疗效评价 [J].介入放射学杂志,2018,27(10):966.
LIU Ya,LV Weifu,CHENG Delei,et al.Efficacy evaluation of intravenous chemotherapy combined with 125I seed implantation in treating advanced non- small cell lung cancer[J].journal interventional radiology,2018,27(03):966.
[6]刘宝东.非小细胞肺癌射频消融热点问题探讨 [J].介入放射学杂志,2018,27(11):1013.
Discussion on hot issues concerning radiofrequency ablation of non- small cell lung cancer LIU Baodong[J].journal interventional radiology,2018,27(03):1013.
[7]刘宝东,胡 牧,刘 磊,等.射频消融联合表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变非小细胞肺癌的临床价值 [J].介入放射学杂志,2018,27(11):1036.
LIU Baodong,HU Mu,LIU Lei,et al.Radiofrequency ablation combined with EGFR- TKIs for EGFR mutant non- small cell lung cancer： its clinical application[J].journal interventional radiology,2018,27(03):1036.
[8]唐钢琴,赵振华,梁晓超.非小细胞肺癌患者射频消融治疗后血清miR-28-3p表达量变化及意义[J].介入放射学杂志,2019,28(09):887.
TANG Gangqin,ZHAO Zhenhua,LIANG Xiaochao..Changes and significance of serum miRNA-28-3p expression in patients with non-small cell lung cancer after radiofrequency ablation[J].journal interventional radiology,2019,28(03):887.
[9]何闯,吴蔚,袁晶,等.CT引导下穿刺活检对ⅠA期非小细胞肺癌疾病无进展生存期和总生存期的影响[J].介入放射学杂志,2020,29(04):372.
HE Chuang,WU Wei,YUAN Jing,et al. The influence of CT-guided needle biopsy on disease-free progressive survival and overall survival in patients with stage ⅠA non-small cell lung cancer[J].journal interventional radiology,2020,29(03):372.
[10]周大治,张雨欣,汤 庆,等.超声引导胸膜活检肺癌基因诊断的临床应用[J].介入放射学杂志,2020,29(07):690.
ZHOU Dazhi,ZHANG Yuxin,TANG Qing,et al.Clinial application of ultrasound- guided pleural biopsy in gene diagnosis of lung cancer[J].journal interventional radiology,2020,29(03):690.